SCHEMBL4794282

SCHEMBL4794282

c1ccc(-c2cc(-c3ccccc3)n(-c3ccccc3)c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
COMT P21964 1/20 0.50
KMT2A Q03164 2/20 0.44
GLO1 Q04760 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
HSP90AA1 P07900 2/20 0.41
ALDH1A1 P00352 5/20 0.41
PKM P14618 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTT P42858 2/20 0.39
HPGD P15428 2/20 0.39
CCNB2 O95067 1/20 0.39
CDK1 P06493 1/20 0.39
CCNB1 P14635 1/20 0.39
CDK5 Q00535 1/20 0.39
CDK5R1 Q15078 1/20 0.39
CCNB3 Q8WWL7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10128495 0.80 L3MBTL1 (0.53) COMTKMT2AGLO1L3MBTL1HSP90AA1
SCHEMBL17916163 0.80 ALDH1A1 (0.52) COMTKMT2ARAB9ANPC1ALDH1A1
SCHEMBL438086 0.79 ALDH1A1 (0.57) COMTKMT2AL3MBTL1ALDH1A1PKM
SCHEMBL18947280 0.78 COMT (0.53) COMTKMT2ARAB9ANPC1HSP90AA1
SCHEMBL9558331 0.78 TET2 (0.40) COMTRAB9ANPC1HSP90AA1ALDH1A1
SCHEMBL15089192 0.73 GLO1 (0.42) COMTKMT2AGLO1L3MBTL1RAB9A
SCHEMBL10513428 0.71 ALDH1A1 (0.50) COMTKMT2AGLO1L3MBTL1RAB9A
SCHEMBL347805 0.70 PCSK9 (0.53) COMTKMT2ARAB9ANPC1ALDH1A1
Biphenyl SCHEMBL21647236 0.67 ALDH1A1 (0.90) RAB9ANPC1ALDH1A1MAPTSMN1; SMN2
Biphenyl SCHEMBL547965 0.67 ALDH1A1 (0.90) RAB9ANPC1ALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1889617-A1 Triphenyl modified 5-membered heterocycles and their use as anticancer and antiflammatory agents Freie Universität Berlin (DE) 2008-02-20 EP claimed
CN-114078444-B Pixel circuit and display device using the same 乐金显示有限公司 2024-02-13 CN disclosed
US-10065976-B2 Titanium (IV) compounds and methods of forming heterocyclic compounds using same REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2018-09-04 US disclosed
US-20170158718-A9 TITANIUM (IV) COMPOUNDS AND METHODS OF FORMING HETEROCYCLIC COMPOUNDS USING SAME REGENTS OF THE UNIVERSITY OF MINNESOTA 2017-06-08 US disclosed
US-20170158718-A9 TITANIUM (IV) COMPOUNDS AND METHODS OF FORMING HETEROCYCLIC COMPOUNDS USING SAME REGENTS OF THE UNIVERSITY OF MINNESOTA 2017-06-08 US disclosed
US-20160200746-A1 TITANIUM (IV) COMPOUNDS AND METHODS OF FORMING HETEROCYCLIC COMPOUNDS USING SAME UNIV MINNESOTA (US) 2016-07-14 US disclosed
US-20160200746-A1 TITANIUM (IV) COMPOUNDS AND METHODS OF FORMING HETEROCYCLIC COMPOUNDS USING SAME UNIV MINNESOTA (US) 2016-07-14 US disclosed
EP-1889617-A1 Triphenyl modified 5-membered heterocycles and their use as anticancer and antiflammatory agents Freie Universität Berlin (DE) 2008-02-20 EP disclosed
WO-2008006626-A1 TRIPHENYL MODIFIED 5-MEMBERED HETEROCYCLES AND THEIR USE AS ANTICANCER AND ANTIINFLAMMATORY AGENTS FREIE UNIVERSITÄT BERLIN (DE) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160200746-A1 TITANIUM (IV) COMPOUNDS AND METHODS OF FORMING HETEROCYCLIC COMPOUNDS USING SAME TERT, PIK3C3, TPI1 COMT 4/4885KMT2A 234/4885GLO1 600/4885
US-20170158718-A9 TITANIUM (IV) COMPOUNDS AND METHODS OF FORMING HETEROCYCLIC COMPOUNDS USING SAME TERT, PIK3C3, TPI1 COMT 4/4885KMT2A 234/4885GLO1 600/4885
US-10065976-B2 Titanium (IV) compounds and methods of forming heterocyclic compounds using same TERT, PIK3C3, TPI1 COMT 4/4885KMT2A 234/4885GLO1 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.